📢 Gate Square #MBG Posting Challenge# is Live— Post for MBG Rewards!
Want a share of 1,000 MBG? Get involved now—show your insights and real participation to become an MBG promoter!
💰 20 top posts will each win 50 MBG!
How to Participate:
1️⃣ Research the MBG project
Share your in-depth views on MBG’s fundamentals, community governance, development goals, and tokenomics, etc.
2️⃣ Join and share your real experience
Take part in MBG activities (CandyDrop, Launchpool, or spot trading), and post your screenshots, earnings, or step-by-step tutorials. Content can include profits, beginner-friendl
Conoah and Nuocheng Jianhua jointly announced a licensing agreement with Prolium for CD20xCD3 bispecific antibodies
On January 20th, JIN10 News reported that Connoa and NovaQuest jointly announced that the two companies and their joint venture have reached a licensing agreement with Prolium Bioscience, authorizing Prolium to develop and commercialize the CD20×CD3 bispecific antibody ICP-B02 (CM355). According to the protocol, Prolium will have the rights to develop, register, produce, and commercialize ICP-B02 in the global non-oncology field and the oncology field outside of Asia. NovaQuest and Connoa will receive a total payment of up to $520 million, including upfront and near-term payments, as well as additional payments for achieving clinical development, registration, and commercialization milestones, and both parties will receive a minority equity stake in Prolium. In addition, NovaQuest and Connoa will also receive tiered royalty payments based on future net sales of the product.